Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Two projects awarded under the 2023 "Subsidy scheme for promising care" in the Netherlands

In March 2023, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which were awarded under round 7 of the subsidy scheme for Promising care in 2023:

  • Repetitive transcranial magnetic stimulation in paresis due to the cerebral infarction or cerebral hemorrhage;
  • Focal therapy in intermediate risk prostate cancer with a life expectancy of at least ten years

The research for repetitive transcranial magnetic stimulation (continuous theta burst stimulation), in addition to hand-arm rehabilitation training in adult patients with paresis of one arm due to a first cerebral infarction or cerebral hemorrhage was awarded a subsidy within the framework of the "Subsidy scheme for promising care". The project will start in October 2023 and will last for six years. After the completion of the project, the research results will be submitted to the ZIN around October 2029 for the decision about inclusion in Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for April 2030.

The research on focal therapy (including high-intensity focused ultrasound ablation, MRI-guided transurethral ultrasound ablation, and irreversible electroporation) in men aged 40 years and older with newly diagnosed, intermediate risk prostate cancer and a life expectancy of at least ten years was awarded a subsidy within the framework of the "Subsidy scheme for promising care". The project will start in June 2023 and will last for six years. After the completion of the project, the research results will be submitted to the Dutch Healthcare Institute (ZIN) around June 2029 for the decision about inclusion in the Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for February 2030.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.